Dialysis specialist DaVita HealthCare Partners (DVA 1.69%) has a new bean counter.
The Denver-based renal health care specialist announced today that Garry E. Menzel, Ph.D., will join the company in mid-Sptember as senior VP of finance, and will take on the role of chief financial officer the day after the company files its third-quarter report with the SEC. The quarter ends Sept. 30. Jim Hilger, who has served as DaVita's interim CFO since 2012, will continue in his role as the company's chief accounting officer, a position he has held since 2010.
Menzel, 48, was most recently the COO and CFO at biopharmaceutical Regulus Therapeutics, where he served since 2008. Before that, he had a 14-year career on Wall Street where he was a managing director and global head of life sciences for Credit Suisse and of biotechnology for Goldman Sachs. Menzel also spent several years as a strategy consultant for Bain & Company.
Belieiving they've found an executive with a versatile skill set, DaVita HealthCare Partners Co-Chairman and CEO Kent Thiry said, "Given the nimbleness that is required for all health care providers we are excited to have Garry join our leadership team."
DaVita's previous CFO, Luis Borgen, who had been in the position for two years, resigned in April 2012 to take a similar job with loose-leaf tea maker Davids Tea, a privately held VC-backed company.
